Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2015 3
2016 7
2017 8
2018 8
2019 14
2020 20
2021 11
2022 10
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: cerbelli b. BMC Cancer. 2024 Apr 17;24(1):487. doi: 10.1186/s12885-024-12249-y. BMC Cancer. 2024. PMID: 38632499 Free PMC article. No abstract available.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: cerbelli b. BMC Cancer. 2024 Apr 8;24(1):430. doi: 10.1186/s12885-024-12155-3. BMC Cancer. 2024. PMID: 38589857 Free PMC article.
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. Ivanova M, et al. Among authors: cerbelli b. Hum Pathol. 2024 Feb;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Epub 2024 Jan 24. Hum Pathol. 2024. PMID: 38278450
Clinical and histological features of patients with primary Sjögren's syndrome and autoimmune thyroiditis: a national multicentre cross-sectional study.
Colafrancesco S, Celia AI, Baldini C, Quartuccio L, Bartoloni E, Carubbi F, Orlandi M, Barbati C, Pignataro MG, Cerbelli B, Giordano C, Ferro F, Gattamelata A, Giardina F, Izzo R, Longhino S, De Vita S, Gerli R, Giacomelli R, Conti F, Priori R. Colafrancesco S, et al. Among authors: cerbelli b. Clin Exp Rheumatol. 2023 Dec;41(12):2389-2396. doi: 10.55563/clinexprheumatol/eh36vs. Epub 2023 Dec 23. Clin Exp Rheumatol. 2023. PMID: 38149510 Free article.
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.
Cerbelli B, Cirillo A, Pomati G, Pernazza A, Ascione A, Pisegna S, Pisano A, Leopizzi M, Pignataro MG, Costarelli L, Mulè A, Vecchione A, Catalano P, Coppola L, Perrone G, Perracchio L, Anemona L, Mastracchio A, Nardi S, Reitano R, Massari A, Grillo LR, Liberati F, Della Rocca C, Marchetti P, Botticelli A, D'Amati G. Cerbelli B, et al. Tumori. 2024 Feb;110(1):44-48. doi: 10.1177/03008916231196781. Epub 2023 Sep 19. Tumori. 2024. PMID: 37726962
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: cerbelli b. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
88 results